Last reviewed · How we verify
GSK Biologicals' - GSK2340272A
GSK Biologicals' - GSK2340272A is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.
At a glance
| Generic name | GSK Biologicals' - GSK2340272A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults (PHASE3)
- Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults (PHASE3)
- Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children (PHASE3)
- Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults (PHASE3)
- Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults (PHASE3)
- Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A) (PHASE2)
- Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children (PHASE2)
- Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Biologicals' - GSK2340272A CI brief — competitive landscape report
- GSK Biologicals' - GSK2340272A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Biologicals' - GSK2340272A
What is GSK Biologicals' - GSK2340272A?
GSK Biologicals' - GSK2340272A is a Biologic drug developed by GlaxoSmithKline.
Who makes GSK Biologicals' - GSK2340272A?
GSK Biologicals' - GSK2340272A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GSK Biologicals' - GSK2340272A in?
GSK Biologicals' - GSK2340272A is in Phase 2.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Compare: GSK Biologicals' - GSK2340272A vs similar drugs
- Pricing: GSK Biologicals' - GSK2340272A cost, discount & access